肿瘤血管抑制剂的研究历史、现状和发展前景

被引：25

作者：

李树婷

孙燕

机构：

[1] 中国医学科学院肿瘤医院新药临床研究(GCP)中心

来源：

癌症进展 | 2003年 / 01期

关键词：

抑制剂; 浮选药剂; 肿瘤血管; 内皮抑素; 临床研究; 血管内皮细胞生长因子; 血管生成抑制素; 剂量限制性毒性; 新生血管; 肿瘤细胞;

D O I：

暂无

中图分类号：

R979.1 [抗肿瘤、抗癌药物];

学科分类号：

摘要：

通过阻断肿瘤的新生血管达到抑制肿瘤发展的概念自提出以来转眼已经32年了。在动物实验中看到令人吃惊的疗效后,这种从杀灭肿瘤细胞到“饿死”肿瘤细胞的途径曾经被认为是肿瘤治疗中的革命性尝试。但在临床上其效果并不理想令人颇感困惑。连Folkman教授本人也不得不承认“我们治愈的是老鼠而不是人”。通过偶然的药物不良反应“反应停事件”,有心的学者看到了这类制剂的威力,又导致了临床新一轮探索的高潮,但近两年来仍然未有突破性结果。通过几十年的探索、失败、再研究,我们能够更加理性地对待这一领域中的问题吗?前进的路在何方?临床研究何时能走出低谷?本文希望能通过对过去的回顾,介绍研究现状,并结合我们的有限经验对以上问题提出一些看法。

引用

页码：80 / 87+23 +23

页数：9

共 18 条

[1]

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growthin vivo. Kim K J,Li B,Winer J,et al. Nature . 1993

[2]

A dose finding study of an oral antiangiogenesis inhibitor, NM-3-Safety profile and effects on surrogate markers with once-daily dosing. P Soulie. Proceedings of the American Society of Clinical Oncology . 2003

[3]

Phase I clinical trial of recombinant human endostatin in patients with solid tumors: pharmacokiedtic, safety and efficacy analysis using surrogate endpoints of tissue and radiologic response. Herbst RS,Tran HT,Mullani NA. Proceedings of the American Society of Clinical Oncology . 2001

[4]

Phsar I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with Ever metasitases. J. Drevs,et al. Proceedings of the American Society of Clinical Oncology . 2003

[5]

Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. O’Reilly M S,Holmgren L,Shing Y,et al. Cell . 1994

[6]

Clinical translation of angiogenesis inhibitors. Kerbel R,Folkman J. Nature Reviews Cancer . 2002

[7]

Angiogenesis research: Looking for new ways to measure success. Roy S Herbst. Oncoloy . 2001

[8]

A phase I safety and pharmacokinetic (PK) study of continuous intravenous rhEndostatin followed by subcutaneous (s. c.) adminidtration in patients with advanced cancers. A H Hansma,et al. Proceedings of the American Society of Clinical Oncology . 2002

[9]

Bevacizumab (Anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (ADVCRC) : an interim tox icity analysis of the Eastern Cooperative Oncology Group ( ECOG) Study E3200. A. B. Benson,et al. Proe ASCO . 2003

[10]

Antiangiogenic therapy with CELECOXIB and weekly paclitaxel as second line treatment for advanced non small cell lung cancer (NSCLC): A phase Ⅱ study. S C Stani. Proceedings of the American Society of Clinical Oncology . 2003

← 1 2 →